Viridian Therapeutics, Inc.

NasdaqCM:VRDN Stock Report

Market Cap: US$1.6b

Viridian Therapeutics Valuation

Is VRDN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VRDN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VRDN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VRDN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VRDN?

Key metric: As VRDN barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for VRDN. This is calculated by dividing VRDN's market cap by their current book value.
What is VRDN's PB Ratio?
PB Ratio3x
BookUS$518.61m
Market CapUS$1.60b

Price to Book Ratio vs Peers

How does VRDN's PB Ratio compare to its peers?

The above table shows the PB ratio for VRDN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average42.3x
INBX Inhibrx
154.5x9.1%US$1.8b
VIR Vir Biotechnology
0.7x1.0%US$954.4m
SPRY ARS Pharmaceuticals
6.6x69.8%US$1.3b
AMAM Ambrx Biopharma
7.3x-9.4%US$1.8b
VRDN Viridian Therapeutics
3x32.1%US$1.6b

Price-To-Book vs Peers: VRDN is good value based on its Price-To-Book Ratio (3x) compared to the peer average (42.3x).

Price to Book Ratio vs Industry

How does VRDN's PB Ratio compare vs other companies in the US Biotechs Industry?

62 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$496.96m
AMRN Amarin
0.4x-7.7%US$201.84m
ACET Adicet Bio
0.4x6.7%US$84.87m
IMAB I-Mab
0.4x1.8%US$77.61m
VRDN 3.0xIndustry Avg. 1.8xNo. of Companies81PB01.63.24.86.48+
62 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: VRDN is expensive based on its Price-To-Book Ratio (3x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is VRDN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VRDN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VRDN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VRDN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$19.79
US$40.63
+105.3%
21.2%US$61.00US$22.00n/a16
Nov ’25US$22.28
US$39.25
+76.2%
21.6%US$56.00US$22.00n/a16
Oct ’25US$23.61
US$39.25
+66.2%
21.6%US$56.00US$22.00n/a16
Sep ’25US$14.68
US$35.19
+139.7%
23.2%US$46.00US$20.00n/a16
Aug ’25US$16.28
US$35.19
+116.1%
23.4%US$46.00US$20.00n/a16
Jul ’25US$13.21
US$35.19
+166.4%
23.4%US$46.00US$20.00n/a16
Jun ’25US$11.95
US$36.50
+205.4%
21.7%US$46.00US$20.00n/a14
May ’25US$13.81
US$39.36
+185.0%
12.0%US$46.00US$30.00n/a14
Apr ’25US$17.26
US$39.36
+128.0%
12.0%US$46.00US$30.00n/a14
Mar ’25US$19.89
US$38.67
+94.4%
13.6%US$46.00US$29.00n/a15
Feb ’25US$20.00
US$39.27
+96.3%
14.9%US$50.00US$29.00n/a15
Jan ’25US$21.78
US$39.33
+80.6%
14.8%US$50.00US$29.00n/a15
Dec ’24US$17.22
US$39.80
+131.1%
16.1%US$50.00US$29.00n/a15
Nov ’24US$12.60
US$41.36
+228.2%
16.5%US$57.00US$30.00US$22.2814
Oct ’24US$15.34
US$43.53
+183.8%
12.5%US$57.00US$35.00US$23.6115
Sep ’24US$19.11
US$44.00
+130.2%
12.7%US$57.00US$35.00US$14.6816
Aug ’24US$18.65
US$46.00
+146.6%
11.1%US$57.00US$36.00US$16.2816
Jul ’24US$23.79
US$46.13
+93.9%
10.8%US$57.00US$40.00US$13.2116
Jun ’24US$24.50
US$46.13
+88.3%
11.1%US$57.00US$40.00US$11.9515
May ’24US$28.64
US$46.79
+63.4%
10.2%US$57.00US$40.00US$13.8114
Apr ’24US$25.44
US$47.38
+86.3%
12.8%US$62.00US$40.00US$17.2613
Mar ’24US$33.06
US$46.92
+41.9%
14.6%US$62.00US$35.00US$19.8912
Feb ’24US$37.30
US$47.08
+26.2%
14.7%US$62.00US$35.00US$20.0012
Jan ’24US$29.21
US$43.17
+47.8%
15.5%US$57.00US$33.00US$21.7812
Dec ’23US$26.04
US$42.20
+62.1%
16.1%US$57.00US$33.00US$17.2210
Nov ’23US$19.76
US$43.22
+118.7%
14.6%US$57.00US$37.00US$12.609

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%